Literature DB >> 24837783

Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection.

Elena E Giorgi1, Harikrishnan Balachandran2, Mark Muldoon3, Norman L Letvin2, Barton F Haynes4, Bette T Korber5, Sampa Santra6.   

Abstract

An effective HIV-1 vaccine should elicit sufficient breadth of immune recognition to protect against the genetically diverse forms of the circulating virus. Evaluation of the breadth and magnitude of cellular immune responses to epitope variants is important for HIV-1 vaccine assessment. We compared HIV-1 Gag-specific T-lymphocyte responses in 20 HIV-1-infected individuals representing two different HIV-1 subtypes, B and C. By assessing T lymphocyte responses with peptides based on natural HIV-1 variants, we found evidence for limited cross-reactivity and significantly enhanced within-clade responses among clade B-infected subjects, and not among clade C-infected subjects.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cross-clade response; HIV-1; T lymphocyte

Mesh：

Substances：

Year:  2014        PMID： 24837783      PMCID： PMC4084750          DOI： 10.1016/j.vaccine.2014.04.040

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  15 in total

1.  Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

Authors:  Marcus Altfeld; Jan van Lunzen; Nicole Frahm; Xu G Yu; Claus Schneider; Robert L Eldridge; Margaret E Feeney; Dirk Meyer-Olson; Hans-Juergen Stellbrink; Bruce D Walker
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development.

Authors:  H Cao; P Kanki; J L Sankalé; A Dieng-Sarr; G P Mazzara; S A Kalams; B Korber; S Mboup; B D Walker
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  In a mixed subtype epidemic, the HIV-1 Gag-specific T-cell response is biased towards the infecting subtype.

Authors:  Christof Geldmacher; Jeffrey R Currier; Martina Gerhardt; Antelmo Haule; Leonard Maboko; Deborah Birx; Clive Gray; Andreas Meyerhans; Josephine Cox; Michael Hoelscher
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

4.  Comprehensive epitope analysis of cross-clade Gag-specific T-cell responses in individuals with early HIV-1 infection in the US epidemic.

Authors:  Uma Malhotra; Jessica Nolin; James I Mullins; M Juliana McElrath
Journal:  Vaccine       Date:  2006-08-10       Impact factor: 3.641

5.  Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences.

Authors:  Laura E Valentine; Shari M Piaskowski; Eva G Rakasz; Nathan L Henry; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

6.  Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation.

Authors:  Fusheng Li; Uma Malhotra; Peter B Gilbert; Natalie R Hawkins; Ann C Duerr; Juliana M McElrath; Lawrence Corey; Steven G Self
Journal:  Vaccine       Date:  2006-06-27       Impact factor: 3.641

7.  Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition.

Authors:  Banson Barugahare; Chris Baker; Okumu K'Aluoch; Richard Donovan; Mohamed Elrefaei; Mark Eggena; Norman Jones; Steven Mutalya; Cissy Kityo; Peter Mugyenyi; Huyen Cao
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

8.  Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity.

Authors:  Michael S Bennett; Hwee L Ng; Ayub Ali; Otto O Yang
Journal:  J Infect Dis       Date:  2008-02-01       Impact factor: 5.226

9.  Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences.

Authors:  Marcus Altfeld; Marylyn M Addo; Raj Shankarappa; Paul K Lee; Todd M Allen; Xu G Yu; Almas Rathod; Jason Harlow; Kristin O'Sullivan; Mary N Johnston; Philip J R Goulder; James I Mullins; Eric S Rosenberg; Christian Brander; Bette Korber; Bruce D Walker
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  Phenotypic properties of transmitted founder HIV-1.

Authors:  Nicholas F Parrish; Feng Gao; Hui Li; Elena E Giorgi; Hannah J Barbian; Erica H Parrish; Lara Zajic; Shilpa S Iyer; Julie M Decker; Amit Kumar; Bhavna Hora; Anna Berg; Fangping Cai; Jennifer Hopper; Thomas N Denny; Haitao Ding; Christina Ochsenbauer; John C Kappes; Rachel P Galimidi; Anthony P West; Pamela J Bjorkman; Craig B Wilen; Robert W Doms; Meagan O'Brien; Nina Bhardwaj; Persephone Borrow; Barton F Haynes; Mark Muldoon; James P Theiler; Bette Korber; George M Shaw; Beatrice H Hahn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-29       Impact factor: 11.205
View more
  2 in total

1.  Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.

Authors:  Sandrine L Hulot; Bette Korber; Elena E Giorgi; Nathan Vandergrift; Kevin O Saunders; Harikrishnan Balachandran; Linh V Mach; Michelle A Lifton; Giuseppe Pantaleo; Jim Tartaglia; Sanjay Phogat; Bertram Jacobs; Karen Kibler; Beatriz Perdiguero; Carmen E Gomez; Mariano Esteban; Margherita Rosati; Barbara K Felber; George N Pavlakis; Robert Parks; Krissey Lloyd; Laura Sutherland; Richard Scearce; Norman L Letvin; Michael S Seaman; S Munir Alam; David Montefiori; Hua-Xin Liao; Barton F Haynes; Sampa Santra
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

2.  Evaluation of T-activated proteins as recall antigens to monitor Epstein-Barr virus and human cytomegalovirus-specific T cells in a clinical trial setting.

Authors:  Nina Körber; Uta Behrends; Ulrike Protzer; Tanja Bauer
Journal:  J Transl Med       Date:  2020-06-17       Impact factor: 5.531
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.